Enorama Pharma AB (OSTO:ERMA) Total Operating Expense: kr49.70 Mil (TTM As of Mar. 2026)


OSTO:ERMA Enorama Pharma AB OSTO:ERMA
28 GF Score
Price kr0.26
GF Value kr0.41
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Enorama Pharma AB Total Operating Expense?

Enorama Pharma AB OSTO:ERMA -4.14% 28 Total Operating Expense is kr49.70 Mil as of Mar. 2026. GuruFocus rates OSTO:ERMA with a GF Score™ of 28/100 and a GF Value™ of kr0.41 (Possible Value Trap). The stock has 4 warning signs investors should review.

Enorama Pharma AB's Total Operating Expense for the three months ended in Mar. 2026 was kr10.83 Mil. Enorama Pharma AB's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was kr49.70 Mil.

Enorama Pharma AB Total Operating Expense Related Terms

Enorama Pharma AB Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Enorama Pharma AB's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enorama Pharma AB Total Operating Expense Chart

Enorama Pharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 31.03 41.35 37.92 51.30 47.08

Enorama Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.89 12.86 11.07 14.94 10.83
OSTO:ERMA
28GF Score
Enorama Pharma AB OSTO:ERMA
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enorama Pharma AB Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr49.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of kr49.70 Mil mean?
Enorama Pharma AB (OSTO:ERMA) has a Total Operating Expense of kr49.70 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Enorama Pharma AB and its competitors.
Is Enorama Pharma AB's Total Operating Expense too high?
Enorama Pharma AB's current Total Operating Expense is kr49.70 Mil. Overall, Enorama Pharma AB has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Enorama Pharma AB's Total Operating Expense compare to ZTS and UTHR?
Enorama Pharma AB's Total Operating Expense of kr49.70 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Enorama Pharma AB and its competitors. Enorama Pharma AB's current Total Operating Expense is kr49.70 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enorama Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Enorama Pharma AB (OSTO:ERMA) is currently considered Possible Value Trap. The stock's GF Value™ is kr0.41, compared to a current price of kr0.26 — trading 37.8% below its estimated fair value. The current Total Operating Expense is kr49.70 Mil. Enorama Pharma AB's overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Enorama Pharma AB (OSTO:ERMA), the current Total Operating Expense is kr49.70 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enorama Pharma AB (OSTO:ERMA) Overvalued in 2026?

Based on GuruFocus' analysis, Enorama Pharma AB stock appears to be undervalued. The current stock price of kr0.26 is trading 37.8% below its estimated GF Value™ of kr0.41. GuruFocus considers Enorama Pharma AB to be Possible Value Trap.

Key valuation signals for OSTO:ERMA:

  • Total Operating Expense: kr49.70 Mil
  • GF Value™: kr0.41 vs. price of kr0.26 (37.8% below fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the OSTO:ERMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Enorama Pharma AB Business Description

Address Vastra Varvsgatan 19, Malmo, SWE, SE-211 77
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
28GF Score

Get the complete analysis for OSTO:ERMA

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.26
Price
kr0.41
GF Value